• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用TOOKAD® Soluble(WST11)进行血管靶向光动力疗法治疗局限性前列腺癌:自动预处理计划的效率

Vascular targeted photodynamic therapy with TOOKAD® Soluble (WST11) in localized prostate cancer: efficiency of automatic pre-treatment planning.

作者信息

Betrouni N, Boukris S, Benzaghou F

机构信息

INSERM, U1189, 1 Avenue Oscar Lambret, Cedex 08, 59037, Lille, France.

Medical Department, Steba biotech, 32 Boulevard Flandrin, Paris, France.

出版信息

Lasers Med Sci. 2017 Aug;32(6):1301-1307. doi: 10.1007/s10103-017-2241-7. Epub 2017 Jun 1.

DOI:10.1007/s10103-017-2241-7
PMID:28569345
Abstract

Vascular targeted photodynamic therapy (VTP) with WST11 is a novel non-thermal focal treatment for localized prostate cancer that has shown favorable and early efficacy results in previously published studies. In this work, we investigate the efficiency of automatic dosimetric treatment planning. An action model established in a previous study was used in an image-guided optimization scheme to define the personalized optimal light dose for each patient. The calculated light dose is expressed as the number of optical cylindrical fibers to be used, their positions according to an external insertion grid, and the lengths of their diffuser parts. Evaluation of the method was carried out on data collected from 17 patients enrolled in two multi-centric clinical trials. The protocol consisted of comparing the method-simulated necrosis to the result observed on day 7 MR enhanced images. The method performances showed that the final result can be estimated with an accuracy of 10%, corresponding to a margin of 3 mm. In addition, this process was compatible with clinical conditions in terms of calculation times. The overall process took less than 10 min. Different aspects of the VTP procedure were already defined and optimized. Personalized treatment planning definition remained as an issue needing further investigation. The method proposed herein completes the standardization of VTP and opens new pathways for the clinical development of the technique.

摘要

采用WST11的血管靶向光动力疗法(VTP)是一种针对局限性前列腺癌的新型非热聚焦治疗方法,在先前发表的研究中已显示出良好的早期疗效。在这项工作中,我们研究了自动剂量治疗计划的效率。在图像引导优化方案中使用先前研究中建立的作用模型,为每位患者定义个性化的最佳光剂量。计算出的光剂量表示为要使用的光学圆柱形光纤数量、它们根据外部插入网格的位置以及它们的扩散器部分的长度。对从参与两项多中心临床试验的17名患者收集的数据进行了该方法的评估。该方案包括将方法模拟的坏死情况与第7天磁共振增强图像上观察到的结果进行比较。该方法的性能表明,最终结果的估计精度可达10%,对应边缘为3毫米。此外,就计算时间而言,该过程与临床条件兼容。整个过程耗时不到10分钟。VTP程序的不同方面已经得到定义和优化。个性化治疗计划的定义仍是一个需要进一步研究的问题。本文提出的方法完善了VTP的标准化,并为该技术的临床发展开辟了新途径。

相似文献

1
Vascular targeted photodynamic therapy with TOOKAD® Soluble (WST11) in localized prostate cancer: efficiency of automatic pre-treatment planning.使用TOOKAD® Soluble(WST11)进行血管靶向光动力疗法治疗局限性前列腺癌:自动预处理计划的效率
Lasers Med Sci. 2017 Aug;32(6):1301-1307. doi: 10.1007/s10103-017-2241-7. Epub 2017 Jun 1.
2
TOOKAD(®) Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer.TOOKAD(®) 可溶性血管靶向光动力(VTP)疗法:确定局部前列腺癌的最佳治疗条件和评估疗效。
BJU Int. 2013 Oct;112(6):766-74. doi: 10.1111/bju.12265.
3
Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapy.使用WST11-血管靶向光动力(VTP)疗法确定实现局限性前列腺癌微创聚焦消融的最佳药物剂量和光剂量指数。
BJU Int. 2015 Dec;116(6):888-96. doi: 10.1111/bju.12816. Epub 2015 Apr 21.
4
Vascular-targeted photodynamic therapy with TOOKAD® Soluble in localized prostate cancer: standardization of the procedure.使用TOOKAD®可溶性制剂进行的血管靶向光动力疗法治疗局限性前列腺癌:治疗程序的标准化
World J Urol. 2015 Jul;33(7):937-44. doi: 10.1007/s00345-015-1535-2. Epub 2015 Mar 19.
5
A model to estimate the outcome of prostate cancer photodynamic therapy with TOOKAD Soluble WST11.采用 TOOKAD Soluble WST11 预测前列腺癌光动力疗法效果的模型。
Phys Med Biol. 2011 Aug 7;56(15):4771-83. doi: 10.1088/0031-9155/56/15/009. Epub 2011 Jul 13.
6
[Treatment of localized prostate cancer by vascular-targeted photodynamic therapy with WST11].[采用WST11进行血管靶向光动力疗法治疗局限性前列腺癌]
Prog Urol. 2014 Nov;24(14):911-4. doi: 10.1016/j.purol.2014.08.002. Epub 2014 Sep 5.
7
Endoscopic vascular targeted photodynamic therapy with the photosensitizer WST11 for benign prostatic hyperplasia in the preclinical dog model.经内镜血管靶向光动力疗法联合光敏剂 WST11 治疗犬良性前列腺增生的临床前研究。
J Urol. 2013 Nov;190(5):1946-53. doi: 10.1016/j.juro.2013.05.014. Epub 2013 May 13.
8
Medium-term Follow-up of Vascular-targeted Photodynamic Therapy of Localized Prostate Cancer Using TOOKAD Soluble WST-11 (Phase II Trials).局部前列腺癌的血管靶向光动力疗法的中期随访:使用 TOOKAD 可溶性 WST-11(II 期试验)。
Eur Urol Focus. 2019 Nov;5(6):1022-1028. doi: 10.1016/j.euf.2018.04.003. Epub 2018 Apr 13.
9
Histopathology of prostate tissue after vascular-targeted photodynamic therapy for localized prostate cancer.前列腺癌局限性经血管靶向光动力治疗后的前列腺组织病理学。
Virchows Arch. 2013 Oct;463(4):547-52. doi: 10.1007/s00428-013-1454-9. Epub 2013 Aug 16.
10
Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses.外照射放疗失败后复发性前列腺癌的血管靶向光动力疗法(帕多泊芬,WST09):递增光剂量的研究
BJU Int. 2008 Aug 5;102(5):556-62. doi: 10.1111/j.1464-410X.2008.07753.x. Epub 2008 May 20.

引用本文的文献

1
Feasibility of antimicrobial photodynamic therapy for treatment of breast abscesses: Retrospective Monte Carlo simulation study.抗菌光动力疗法治疗乳腺脓肿的可行性:回顾性蒙特卡洛模拟研究
Photochem Photobiol. 2025 Mar 4. doi: 10.1111/php.14085.
2
Trial watch: an update of clinical advances in photodynamic therapy and its immunoadjuvant properties for cancer treatment.试验观察:光动力疗法及其免疫佐剂特性在癌症治疗中的临床进展更新。
Oncoimmunology. 2023 Jun 18;12(1):2226535. doi: 10.1080/2162402X.2023.2226535. eCollection 2023.
3
Porphyrin Macrocycles: General Properties and Theranostic Potential.

本文引用的文献

1
Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial.帕利泊芬血管靶向光动力疗法与主动监测治疗低危前列腺癌男性患者(CLIN1001 PCM301):一项开放标签、3 期、随机对照临床试验。
Lancet Oncol. 2017 Feb;18(2):181-191. doi: 10.1016/S1470-2045(16)30661-1. Epub 2016 Dec 20.
2
Vascular-targeted photodynamic therapy with TOOKAD® Soluble in localized prostate cancer: standardization of the procedure.使用TOOKAD®可溶性制剂进行的血管靶向光动力疗法治疗局限性前列腺癌:治疗程序的标准化
World J Urol. 2015 Jul;33(7):937-44. doi: 10.1007/s00345-015-1535-2. Epub 2015 Mar 19.
3
卟啉大环化合物:一般性质与治疗诊断潜能。
Molecules. 2023 Jan 23;28(3):1149. doi: 10.3390/molecules28031149.
4
Photodynamic therapy for prostate cancer: Recent advances, challenges and opportunities.前列腺癌的光动力疗法:最新进展、挑战与机遇
Front Oncol. 2022 Sep 23;12:980239. doi: 10.3389/fonc.2022.980239. eCollection 2022.
5
Photodynamic Inactivation of Microorganisms Using Semisynthetic Chlorophyll Derivatives as Photosensitizers.利用半合成叶绿素衍生物作为光敏剂的微生物光动力灭活。
Molecules. 2022 Sep 6;27(18):5769. doi: 10.3390/molecules27185769.
6
Effects of patient-specific treatment planning on eligibility for photodynamic therapy of deep tissue abscess cavities: retrospective Monte Carlo simulation study.患者特异性治疗计划对深部组织脓肿腔光动力疗法适应证的影响:回顾性蒙特卡罗模拟研究。
J Biomed Opt. 2022 Feb;27(8). doi: 10.1117/1.JBO.27.8.083007.
7
Machine learning for real-time optical property recovery in interstitial photodynamic therapy: a stimulation-based study.用于间质光动力治疗中实时光学特性恢复的机器学习:一项基于刺激的研究。
Biomed Opt Express. 2021 Aug 4;12(9):5401-5422. doi: 10.1364/BOE.431310. eCollection 2021 Sep 1.
8
Growth, Proliferation and Metastasis of Prostate Cancer Cells Is Blocked by Low-Dose Curcumin in Combination with Light Irradiation.低剂量姜黄素联合光照可抑制前列腺癌细胞的生长、增殖和转移。
Int J Mol Sci. 2021 Sep 15;22(18):9966. doi: 10.3390/ijms22189966.
9
Perspectives on interstitial photodynamic therapy for malignant tumors.恶性肿瘤间质光动力疗法的观点。
J Biomed Opt. 2021 Jul;26(7). doi: 10.1117/1.JBO.26.7.070604.
10
A promising anticancer drug: a photosensitizer based on the porphyrin skeleton.一种有前景的抗癌药物:一种基于卟啉骨架的光敏剂。
RSC Med Chem. 2020 Feb 25;11(4):427-437. doi: 10.1039/c9md00558g. eCollection 2020 Apr 1.
TOOKAD® Soluble focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of localized prostate cancer.
TOOKAD® 可溶性聚焦疗法:三项评估局限性前列腺癌微创消融的II期研究的汇总分析。
World J Urol. 2015 Jul;33(7):945-53. doi: 10.1007/s00345-015-1505-8. Epub 2015 Feb 25.
4
Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapy.使用WST11-血管靶向光动力(VTP)疗法确定实现局限性前列腺癌微创聚焦消融的最佳药物剂量和光剂量指数。
BJU Int. 2015 Dec;116(6):888-96. doi: 10.1111/bju.12816. Epub 2015 Apr 21.
5
An image guided treatment platform for prostate cancer photodynamic therapy.一种用于前列腺癌光动力治疗的图像引导治疗平台。
Annu Int Conf IEEE Eng Med Biol Soc. 2013;2013:370-3. doi: 10.1109/EMBC.2013.6609514.
6
Focal therapy of prostate cancer: energies and procedures.前列腺癌的局部治疗:能量与方法。
Urol Oncol. 2013 Feb;31(2):155-67. doi: 10.1016/j.urolonc.2012.05.011. Epub 2012 Jul 12.
7
Elastic image registration for guiding focal laser ablation of prostate cancer: preliminary results.弹性图像配准引导前列腺癌聚焦激光消融术:初步结果。
Comput Methods Programs Biomed. 2012 Oct;108(1):213-23. doi: 10.1016/j.cmpb.2012.04.001. Epub 2012 May 9.
8
A model to estimate the outcome of prostate cancer photodynamic therapy with TOOKAD Soluble WST11.采用 TOOKAD Soluble WST11 预测前列腺癌光动力疗法效果的模型。
Phys Med Biol. 2011 Aug 7;56(15):4771-83. doi: 10.1088/0031-9155/56/15/009. Epub 2011 Jul 13.
9
System for interstitial photodynamic therapy with online dosimetry: first clinical experiences of prostate cancer.间质光动力治疗在线剂量测定系统:前列腺癌的初步临床经验。
J Biomed Opt. 2010 Sep-Oct;15(5):058003. doi: 10.1117/1.3495720.
10
Permanent occlusion of feeding arteries and draining veins in solid mouse tumors by vascular targeted photodynamic therapy (VTP) with Tookad.Tookad 介导的血管靶向光动力疗法(VTP)使实体瘤内的营养动脉和引流静脉永久性闭塞。
PLoS One. 2010 Apr 22;5(4):e10282. doi: 10.1371/journal.pone.0010282.